Lilly’s Alzheimer’s Drug Fails Phase III Clinical Trial

Eli Lilly and Co. announced that solanezumab did not meet the primary endpoint in a Phase III study in patients with mild dementia due to Alzheimer's disease.

While the study results, including many secondary clinical endpoints, favored solanezumab, the magnitudes of treatment differences were small.

The trial enrolled more than 2,100 patients diagnosed with mild dementia due to Alzheimer’s disease. The study includes an 18-month placebo-controlled period followed by an open-label extension.